Pacylex Pharmaceuticals, Inc. focuses on developing precision medicine solutions for cancer. Our proprietary biomarker and therapeutic technologies enable the development of true precision medicine for a range of cancers and build upon a solid understanding of a novel biology.

  • Our first product is a precision medicine based patient selection biomarker & therapeutic combination targeting the NMT/myristoylation pathway
  • Lead candidate is a result of three generations of compounds, has structure-activity relationship information, is orally bioavailable, and has Pk/Pd data. IC50 below 10nM for recombinant human NMT1 with over 50 members of the series with IC50s of 20nM or less
  • Biomarker that confers the sensitivity to our drug is lost in 19 types of cancer at a prevalence that varies from 5-82%, the highest being in hematological malignancies.
  • Through a collaboration with an undisclosed pharmaceutical company (non-binding agreement), breadth of efficacy studies have shown promising results in multiple solid tumour models including small cell lung cancer
  • Multiple mouse efficacy studies show eradication of AML, Burkitts Lymphoma, and DLBCL xenograft tumours in mice with treatment
  • All applicable indications combined lead to a >1.1M biomarker screenings and >150K therapeutic candidate patients per year in North America – >$3.5B annual potential revenue

Our Story

An early discovery demonstrating that many cancer cells seem to lose the expression of a key survival protein showed that it could be possible to target these tumours without affecting normal tissues. This discovery, made at the University of Alberta (U of A) was in-licensed to a newly formed Pacylex to commercialize the use of a diagnostic test that enable the identification of patients with tumours predicted to be sensitive to our lead drug.

Concurrently, a drug development program targeting this same enzyme out of the University of Dundee was underway at about the same time. Working closely with the Dundee group, Pacylex has now in-licensed the rights to Dundee's therapeutic lead drug to complement our companion diagnostic product. By combining these two technologies, Pacylex is developing a promising precision medicine to selectively treat patients with certain types of cancers.

This work was partially funded by in-kind contributions by Eusera, Luc Berthiaume's antibody production company. It is currently supported by the Alberta Cancer Foundation (ACF) and its founders.

Pacylex operates in collaboration with the U of A laboratory as we move forward to jointly develop the background basic research in tandem with clinical efforts.